SBHMY vs TLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SBHMY · SINO BIOPHARMACEUT$14.40 ▲ 0.00%
TLN · Talen Energy$332.92 ▼ 6.46%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SBHMY -24.2%
- TLN -12.5%
Head to head
| Metric | SBHMY | TLN |
|---|---|---|
| Price | $14.40 | $332.92 |
| Change today | ▲ 0.00% | ▼ 6.46% |
| Market cap | $14.50B | $14.48B |
| Return, 3 months | +12.2% | +9.0% |
| Return, year to date | -19.1% | -11.2% |
| Return, 1 year | -24.2% | -9.0% |
| P/E (TTM) | 37.9 | – |
| P/B | 2.6 | 9.2 |
| P/E percentile vs own 5y | – | 24th |
| Dividend yield | 2.13% | – |
| Revenue growth (YoY, latest qtr) | – | +96.1% |
| Net profit growth (YoY) | – | -33.3% |
| Gross margin | – | 42.7% |
| Operating margin | – | 15.3% |
| Net margin | – | -5.7% |
| Return on equity | – | -16.7% |
| Analyst target vs. price | – | +35.8% |
| Analyst buy share | – | 92% |
| RSI (14) | 55 | 44 |
| 30-day volatility | 83.8% | 64.7% |
| Max drawdown, 1 year | -42.0% | -35.6% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SBHMY is the largest of the group by market value.
- TLN has returned the most over the past year.
- TLN has been the calmest stock over the last 30 days.